Sutro Biopharma (STRO) Projected to Post Quarterly Earnings on Monday

Sutro Biopharma (NASDAQ:STRO - Get Free Report) will likely be announcing its Q1 2025 earnings results before the market opens on Monday, May 12th. Analysts expect Sutro Biopharma to post earnings of ($0.63) per share and revenue of $11.61 million for the quarter.

Sutro Biopharma (NASDAQ:STRO - Get Free Report) last posted its quarterly earnings data on Thursday, March 13th. The company reported ($2.96) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($2.10). The firm had revenue of $14.00 million for the quarter, compared to the consensus estimate of $10.44 million. Sutro Biopharma had a negative return on equity of 101.89% and a negative net margin of 77.01%. During the same period in the prior year, the company earned ($1.78) EPS. On average, analysts expect Sutro Biopharma to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Sutro Biopharma Price Performance

NASDAQ:STRO traded up $0.04 during trading hours on Wednesday, hitting $0.99. The company's stock had a trading volume of 2,361,648 shares, compared to its average volume of 1,087,884. The stock has a fifty day simple moving average of $0.88 and a 200-day simple moving average of $1.89. The company has a market capitalization of $83.86 million, a P/E ratio of -0.62 and a beta of 1.77. Sutro Biopharma has a twelve month low of $0.52 and a twelve month high of $5.17.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on STRO shares. Piper Sandler set a $2.00 price target on Sutro Biopharma in a research note on Friday, March 14th. Citizens Jmp downgraded shares of Sutro Biopharma from an "outperform" rating to a "market perform" rating in a report on Friday, March 14th. Wedbush cut Sutro Biopharma from an "outperform" rating to a "neutral" rating and cut their target price for the company from $8.00 to $2.00 in a research report on Friday, March 14th. HC Wainwright reaffirmed a "neutral" rating and issued a $2.00 target price on shares of Sutro Biopharma in a report on Tuesday, April 29th. Finally, Bank of America lowered Sutro Biopharma from a "buy" rating to an "underperform" rating and reduced their price objective for the company from $11.00 to $1.00 in a report on Friday, March 14th. One analyst has rated the stock with a sell rating, five have issued a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $6.63.

About Sutro Biopharma

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.